Navigation Links
Flextronics Announces Change in Control Repurchase Offer for Solectron's 0.50% Senior Convertible Notes
Date:10/31/2007

SINGAPORE, Oct. 31 /PRNewswire-FirstCall/ -- Flextronics International Ltd. (Nasdaq: FLEX) today announced that, in connection with Flextronics's previously announced acquisition of Solectron Corporation on October 1, 2007, Solectron has notified holders of its outstanding 0.50% Convertible Senior Notes due 2034 (CUSIP Nos. 834182 AR 8 and 834182 AS 6) and Solectron's 0.50% Convertible Senior Notes Series B due 2034 (CUSIP No. 834182 AT) (together, the "Convertible Notes") that it will repurchase any Convertible Notes delivered for repurchase pursuant to its offer to repurchase at a cash price equal to 100% of their outstanding principal amount, plus accrued and unpaid interest to, but excluding, the date of repurchase. The indentures governing the Convertible Notes require Solectron to make the offer to repurchase the Convertible Notes as a result of Flextronics's acquisition of Solectron.

U.S. Bank National Association is acting as the paying agent for Solectron's offer to repurchase its Convertible Notes (the "Paying Agent").

In order to have their Convertible Notes repurchased, holders must validly surrender their Convertible Notes to the Paying Agent by 5:00 p.m., New York City time, on November 30, 2007 (the "Submission Deadline"). The repurchase price for all Convertible Notes validly surrendered and not withdrawn by the Submission Deadline shall become due and payable on December 14, 2007 and interest on such Convertible Notes will cease to accrue on and after such date. Solectron will deposit a cash payment equal to the aggregate repurchase price for the Convertible Notes being repurchased with the Paying Agent, which will transmit payments to holders.

The Convertible Notes, which are convertible into a cash payment of $402.41 per $1,000 principal amount, are not currently convertible and Solectron makes no assurances that the Convertible Notes will become convertible again at any time prior to their maturity on February 15, 2034.

Holders of Convertible Notes should carefully read the Change in Control Repurchase Notice issued by Solectron, as it contains important information regarding the procedures to be followed and timing for Solectron's repurchase of the Convertible Notes. Holders of Convertible Notes may obtain copies of the Change in Control Repurchase Notice and delivery instructions for the Convertible Notes by contacting U.S. Bank National Association at (800) 934-6802.

About Flextronics

Headquartered in Singapore (Singapore Reg. No. 199002645H), Flextronics is a leading Electronics Manufacturing Services (EMS) provider focused on delivering complete design, engineering and manufacturing services to automotive, computing, consumer digital, industrial, infrastructure, medical and mobile OEMs. With the acquisition of Solectron, pro forma fiscal year 2007 revenues from continuing operations are more than US$30.0 billion. Flextronics helps customers design, build, ship, and service electronics products through a network of facilities in 35 countries on four continents. This global presence provides design and engineering solutions that are combined with core electronics manufacturing and logistics services, and vertically integrated with components technologies, to optimize customer operations by lowering costs and reducing time to market. For more information, please visit http://www.flextronics.com.


'/>"/>
SOURCE Flextronics International Ltd.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. PM announces a new health care order for India
2. Ramdoss Announces Introduction of RCH-II
3. Britain Announces Third Transfusion Related Mad Cow Case
4. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
5. Tibet Announces the Dalai Lama’s Tour of South Americ
6. NHS announces further Cost cutting Measures
7. Indian PM Announces Of Setting Up India Study Center At Tashkent
8. PowderMed Announces Needle-Less Flu Vaccine
9. Malaysia Announces Prison term On People Donating HIV-Contaminated Blood
10. Australian Government Announces Survey To Tackle Childhood Obesity
11. New Zealand Announces 10-year Plan For Betterment Of Mental Health Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... February 23, 2017 , ... CALNOC, the nation’s first and only ... their upcoming conference – Empowerment, Value and Collaboration – in Seattle, WA on October ... the Virginia Mason Health System in Seattle since 2000. In addition to his role ...
(Date:2/23/2017)... ... February 23, 2017 , ... Curemark, LLC announced today that the Blüm ... in children aged 3-8 with Autism, is now enrolling at three new sites. These ... the United States. , “There are currently no approved drugs that address the ...
(Date:2/23/2017)... ... 23, 2017 , ... Thomas Vas-Don suffered from severe injury due ... was able to successfully recover. In “ Origin & Insertion Charts for Massage Therapists ... the principals of massage, anatomy , trigger points and referral pain patterns ...
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... ... and lobby of a new healthcare contact center in Georgia, PENETRON Specialty Products ... of the nation’s largest healthcare systems recently invested $51 million to purchase and ...
(Date:2/22/2017)... ... 22, 2017 , ... Gevir, a New Zealand-based company that focuses on developing ... coming soon to Amazon.com, the world’s largest online retailer. , The company ... an effective natural treatment for Shelley’s Multiple Sclerosis, which she’d been diagnosed with at ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... 23, 2017 Tillotts Pharma is ... Berlin office was opened in January ... The portfolio includes Entocort ® for the treatment ... of ulcerative colitis, and VistaPrep ® for bowel ... specialty pharmaceutical company focused on the treatment of gastrointestinal ...
(Date:2/23/2017)... MabVax Therapeutics Holdings, Inc . ... announces that it has received notice from the ... initiation a Phase I clinical trial with MVT-1075 ... ( 177 Lu-CHX-A?-DTPA-HuMab5B1) is the Company,s novel fully ... the phase I clinical trial in patients with ...
(Date:2/23/2017)... 2017 Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT) ( ... and dermatology biopharmaceutical company, today announced that it has ... as special advisers to the Company,s Board of ... board on financial and corporate strategy. Provectus ... of up to $2.5 million from Eric Wachter ...
Breaking Medicine Technology: